Keywords: GENova, patents, cancer drugs

GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees

Article | 11 September 2009

US biotechnology firm GENova Biotherapeutics says that it is in the process of acquiring three promising new drug target patents ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in